Immune Design Logo
Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab
December 02, 2018 12:00 ET | Immune Design Corp.
Overall Response Rate (ORR) of 46% in Patients Receiving the Combination TLR4 Biomarker Continued to Show Higher Response Rate for Patients with High TLR4 Expression (71% ORR) Long-term Follow Up...
Immune Design Logo
Immune Design to Present at Piper Jaffray 30th Annual Healthcare Conference
November 20, 2018 08:00 ET | Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...
Immune Design Logo
Immune Design to Present at Jefferies 2018 London Healthcare Conference
November 09, 2018 08:00 ET | Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos...
Immune Design Logo
Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 06, 2018 16:01 ET | Immune Design Corp.
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation...
Immune Design Logo
Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting
November 06, 2018 08:01 ET | Immune Design Corp.
New data further support G100’s broad potential in hematological malignancies and solid tumors SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:...
Immune Design Logo
Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update
October 30, 2018 08:00 ET | Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it...
Immune Design Logo
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
October 11, 2018 16:01 ET | Immune Design Corp.
G100 development to accelerate in follicular lymphoma and beyondCMB305 to be deprioritized to support focus on G100Cash runway extended into 2021Conference call at 2:00 pm Pacific today SEATTLE and...
Immune Design Logo
Immune Design to Present at Upcoming September Investor Conferences
August 30, 2018 08:00 ET | Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior...
Immune Design Logo
Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
August 01, 2018 16:01 ET | Immune Design Corp.
G100 advancing to late-stage development following FDA feedbackConference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design...
Immune Design Logo
Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
July 25, 2018 08:00 ET | Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced...